Lifecore Biomedical (NASDAQ:LFCR – Get Free Report) and RYTHM (NASDAQ:RYM – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Institutional & Insider Ownership
83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 6.0% of RYTHM shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Lifecore Biomedical and RYTHM”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lifecore Biomedical | $128.87 million | 1.89 | -$70.51 million | ($1.86) | -3.45 |
| RYTHM | $70.82 million | 0.42 | -$33.26 million | ($5.27) | -2.61 |
RYTHM has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Lifecore Biomedical has a beta of 0.99, indicating that its share price is 1% less volatile than the S&P 500. Comparatively, RYTHM has a beta of 9.94, indicating that its share price is 894% more volatile than the S&P 500.
Profitability
This table compares Lifecore Biomedical and RYTHM’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lifecore Biomedical | -56.80% | N/A | -29.53% |
| RYTHM | 9.84% | 21.25% | 5.51% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Lifecore Biomedical and RYTHM, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lifecore Biomedical | 2 | 3 | 0 | 0 | 1.60 |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
Lifecore Biomedical presently has a consensus target price of $6.50, suggesting a potential upside of 1.25%. Given Lifecore Biomedical’s stronger consensus rating and higher possible upside, analysts plainly believe Lifecore Biomedical is more favorable than RYTHM.
Summary
Lifecore Biomedical beats RYTHM on 7 of the 13 factors compared between the two stocks.
About Lifecore Biomedical
Lifecore Biomedical, Inc. is a contract development and manufacturing organization (CDMO) focused on sterile injectable pharmaceutical products. The company works with customers on product development, formulation, analytical testing, regulatory support and commercial-scale manufacturing, including fill-finish services. Lifecore also develops and manufactures hyaluronic acid, a biopolymer used in medical products and other applications. Its capabilities support products in areas such as ophthalmology and orthopedics, as well as pharmaceutical and veterinary uses.
About RYTHM
I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight. Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.
Receive News & Ratings for Lifecore Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifecore Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.
